Tests a smartwatch heart monitor in lymphoma and sarcoma survivors
Tests whether a smartwatch can track heart health in adult cancer survivors over time.
Plain-language title generated from the registry record
Registry title: WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT07058064
- Record updated
- 15 October 2025
- Original description
The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.Read full original descriptionShow less
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.
Inclusion: ability to understand study procedures and being willing to comply with them for the entire study length; diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy.
Exclusion: LVEF <50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm; Unwilling or unable to give written informed consent; Participants who have opted out of the Minnesota Research Authorization.